$YCRM Yuengling's Ice Cream Announces an Exclusive

New Post Public Reply Private Reply Replies (0) Message Board
Go Green
261
$YCRM Yuengling's Ice Cream Announces an Exclusive Licensing Agreement with GPO Plus to Produce Yuengling’s Ice Cream Flavored CBD + Cannabinoid Products

ATLANTA, GA and LAS VEGAS, NV, Dec. 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Yuengling’s Ice Cream Corporation (“Yuengling’s”) (OTC PINK: YCRM) is pleased to announce that it has signed an exclusive licensing agreement with GPO Plus, Inc. (OTCQB: GPOX). GPOX will develop a full line of CBD and other hemp derived cannabinoid products based on the iconic flavors of Yuengling’s Ice Cream.

“We are very excited to be working with GPOX”, said Chuck Green, Yuengling’s incoming President and CEO. “As we plan for the relaunch of Yuengling’s Ice Cream in the spring of 2023, we have been thinking of different ways to leverage the Yuengling’s brand. A licensing agreement must be with a quality organization with great products. GPOX fits both those criteria."

Robert Bohorad, Yuengling’s current President and CEO and soon to be COO and CFO, followed up, “While I got the process started, Chuck has been instrumental in advancing discussions with YIC - Online and Retail Distributors and GPOX and getting the agreement signed.”  

In the nutraceutical, hemp derived products and Farm Bill Compliant Delta 8, 9 and 10, THC-o, THC-p, THC-x, THC-b, and other popular hemp derived cannabinoids including HHC, and Kratom segments, GPOX’s DISTRO+ division represents only the highest quality brands that use best in class ingredients. Additional details regarding products, flavors, launch date and where the product will be sold will be provided in a subsequent press release.

Brett H. Pojunis, CEO of GPOX added, “I grew up in New York, where Yuengling’s is a household name and a very popular brand throughout the Northeast.  I am beyond excited to partner with the Yuengling’s Ice Cream family and be tasked to develop the new CBD and Cannabinoid products for such a storied, well known legacy brand. We’re extremely excited about building out the sales channels, based on our complimentary geographic reach, and developing this new suite of products based on the Yuengling’s Ice Cream flavor profiles!”
  
About GPOPlus+ (GPOX)
Headquartered in Las Vegas, Nevada, GPOPlus+ (OTCQB: GPOX) is a brand creation and distribution company focused on independent and regional retailers with an ever-growing product catalog, that uses the power of Group Purchasing to save businesses money, our Mission is to create value for our GPOX Members, partners, suppliers, and shareholders. For more information and to sign up for the Investor Portal, please visit www.GPOPlus.com/ir. 

About DISTRO+
DISTRO+ is a Group Purchasing Organization (GPO) + distributor of premium products for the emerging specialty retailer sector and wholesalers. DISTRO+ proudly represents best-in-class brands focusing on nutraceuticals, hemp derived products including flower, prerolls, gummies, sublingual strips and more utilizing the latest compounds and ingredients such as HHC, Farm Bill Compliant Delta 8, 9 and 10, THC-o, THC-p, THC-x, THC-b, and other popular hemp derived cannabinoids, and Kratom. All of this is backed by a robust technology portal that gives our small and medium sized partners (we call them “Members”) the IT backbone to manage logistics, inventory, payments while shopping from real time product catalogs and inventory. Through the power of Group Purchasing, DISTRO+ offers its network competitive pricing with low MOQs that realize similar discounts as major retailers with large buying power
  
About Yuengling’s Ice Cream (YCRM)
Yuengling’s Ice Cream was founded by American businessman Frank D. Yuengling in 1920 to help support the family brewery during Prohibition, which lasted from January, 1920 to December, 1933. Spun off as a separate company from the brewery in 1935, Yuengling's maintained a strong tradition of making exceptional gourmet ice cream products in central Pennsylvania. The fan-favorite brand advanced its legacy and its renowned dairy quality by using locally sourced dairy ingredients that contain no added hormones. The company discontinued production in 1985 when no family successor emerged. In 2014, the brand was revived and an American classic was re-born. The Yuengling's Ice Cream Corporation, as it has been since 1935, is a separately owned and operated company from D. G. Yuengling & Son, Inc Brewery. After a corporate reorganization in 2022, the company is targeting the relaunch of its storied ice cream flavors in the spring/summer of 2023.

Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include statements regarding expected financial performance and growth information relating to future events. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the control of the Company and its officers and managers, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to; inability to gain or maintain licenses, reliance on unaudited statements, the Company’s need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company’s products, and other risks that are detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. All statements other than statements of historical fact are statements that could be forward-looking statements. You can typically identify these forward-looking statements through use of words such as “may,” “will,” “can” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential,” and other similar words and expressions of the future. The Company expresses its expectations, beliefs and projections in good faith and believes that its expectations reflected in these forward-looking statements are based on reasonable assumptions. However, there is no assurance that these expectations, beliefs and projections will prove to have been correct. Such statements reflect the current views of the Company with respect to its operations and future events, and are subject to certain risks, uncertainties and assumptions relating to its proposed operations, including the risk factors set forth herein. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, the Company’s actual results may vary significantly from those intended, anticipated, believed, estimated, expected or planned. In light of these risks, uncertainties and assumptions, any favorable forward-looking events discussed herein might not be realized and occur. The Company undertakes no obligation to publicly update or revise its forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed description of the risk factors and uncertainties affecting Yuengling’s Ice Cream (YCRM), please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. 

  
Yuengling’s Investor Relation Contacts:
Robert C. Bohorad, President and CEO
Email: IR@yuenglingsicecream.com
Phone: 570-968-4352
www.yuenglingsicecream.com

GPOX Shareholder Success Team+ Investor Relation Contacts:
Brett H. Pojunis, CEO
Email: ir@gpoplus.com  
Shareholder’s Line: 855.935.GPOX (4769)

https://www.globenewswire.com/newsroom/ti?nf=...A5ODQ1MA==
https://ml.globenewswire.com/media/Y2YyMWY3Nz...rporat.png

Source: Yuengling’s Ice Cream Corporation © 2022 GlobeNewswire, Inc.

New to options trading?

Sponsored By: The Options Institute - Cboe Global Markets

Learn all things options from the options experts – everything from free virtual courses and in-person courses, to interactive tools, webinars and office hours – to help you master the heck out of options. Learn Options


Yuengling's Ice Cream Corporation (YCRM) Stock Research Links

YCRM Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG OLED evo W6: UAE Roadshow Starts with a Bang

Updated Category News Views 33

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Continue Reading
Masimo's smartSET™ Revolutionizes Patient Monitoring

Updated Category News Views 30

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Continue Reading
Innventure Faces Major Lawsuit Over Misleading Investors

Updated Category News Views 38

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Continue Reading
Weifang's Cultural Resurgence: A Global Epigraphy Fest

Updated Category News Views 28

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Continue Reading
Voter Events by Valley Community Healthcare Aim to Empower

Updated Category News Views 24

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Continue Reading
AEVEX Facing Class Action Deadline Amid Stock Turmoil

Updated Category News Views 39

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Continue Reading
Hyliion Class Action Deadline Nears for Investors

Updated Category News Views 38

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Technologies Unveiled by LG Innotek at CES 2025

Updated Category News Views 383

Innovative Showcase by LG Innotek at CES 2025 LG Innotek has exciting plans for CES 2025, showcasing its commitment to revolutionizing future mobility. This year, the company aims to highlight its advanced technologies at a well-organized exhibition booth set within the bustling West Hall. A Focus on Future Mobility Technologies At CES 2025, LG Innotek will present a...

Continue Reading
Alumis and ACELYRIN Merger: A New Era for Biopharma Innovation

Updated Category News Views 277

Alumis and ACELYRIN Merge to Forge a New Path in Biopharma The biopharmaceutical landscape is about to witness a significant transformation as Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, INC. (NASDAQ: SLRN) announce their merger. This strategic alliance aims to innovate, develop, and commercialize new therapies for immune-mediated diseases. With top-tier clinical programs...

Continue Reading
Legal Reminder for ICON Shareholders: Act Before Deadline

Updated Category News Views 147

Important Update for ICON plc Shareholders In a significant legal development, shareholders of ICON plc need to be aware of a class action lawsuit that has implications for their investments. If you have incurred losses exceeding $100,000, it is essential to act swiftly, as the deadline for filing lead plaintiff applications is approaching. This lawsuit originates from...

Continue Reading
Corvus Pharmaceuticals to Showcase Innovations at Investment Event

Updated Category News Views 50

Corvus Pharmaceuticals to Present at Major Investment Conference BURLINGAME, Calif. — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a prominent name in the clinical-stage biopharmaceutical sector, is thrilled to announce that its president and CEO, Richard A. Miller, M.D., along with Jeffrey Arcara, the chief business officer, will be participating in one-on-one meetings...

Continue Reading
Discover Promising Dividend Stocks with Robust Growth Potential

Updated Category News Views 122

Exploring Reliable Dividend Stocks with Growth Potential Investors have found that dividend stocks generally offer a compelling annual return averaging 9.2% since 1973, showing less volatility than the broader market index. These investments can provide a steady income stream while also having a significant upside potential. In this article, we delve into three stocks...

Continue Reading